Alkylsulfanyl-1,2,4-triazoles, a New Class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 56, Issue 2, 2013, Pages 437-450

  Polucci, Paolo ^a   Magnaghi, Paola ^a   Angiolini, Mauro ^a   Asa, Daniela ^a   Avanzi, Nilla ^a   Badari, Alessandra ^a   Bertrand, Jay ^a   Casale, Elena ^a   Cauteruccio, Silvia ^a   Cirla, Alessandra ^a   Cozzi, Liviana ^a   Galvani, Arturo ^a   Jackson, Peter K ^b   Liu, Yichin ^b   Magnuson, Steven ^b   Malgesini, Beatrice ^a   Nuvoloni, Stefano ^a   Orrenius, Christian ^a   Sirtori, Federico Riccardi ^a   Riceputi, Laura ^a   Rizzi, Simona ^a   Trucchi, Beatrice ^a   O'Brien, Tom ^b   Isacchi, Antonella ^a   Donati, Daniele ^a   D'Alessio, Roberto ^a   more..

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(5 CYCLOPENTYLSULFANYL 4 PYRIDIN 3 YL 4H [1,2,4]TRIAZOL 3 YL)METHANOL; (5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YL)METHANOL; (5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YLMETHYL)METHYLPHENYLAMINE; (5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YLMETHYL)PHENYLAMINE; 1,2,4 TRIAZOLE DERIVATIVE; 3 (3 BENZYLOXYMETHYL 5 CYCLOPENTYLSULFANYL[1,2,4]TRIAZOL 4 YL)PYRIDINE; 3 (3 CHLOROMETHYL 5 CYCLOPENTYLSULFANYL[1,2,4]TRIAZOL 4 YL)PYRIDINE; 3 (3 CYCLOPENTYLSULFANYL 5 PHENOXYMETHYL[1,2,4]TRIAZOL 4 YL)PHENYLAMINE; 3 (3 CYCLOPENTYLSULFANYL 5 PHENOXYMETHYL[1,2,4]TRIAZOL 4 YL)PYRIDINE; 3 (5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YLMETHOXY)PYRIDINE; 3 CHLOROMETHYL 5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 CYCLOHEXYLOXY 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 CYCLOHEXYLOXYMETHYL 5 ISOPROPYLSULFANYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 CYCLOPENTYLOXY 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 CYCLOPENTYLSULFANYL 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 ISOPROPOXY 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 ISOPROPYLSULFANYL 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 METHANESULFONYL 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE; 3 PHENOXYMETHYL 4 PHENYL 5 (PROPANE 2 SULFONYL) 4H [1,2,4]TRIAZOLE; 3 PHENOXYMETHYL 4 PHENYL 5 PHENYLSULFANYL 4H [1,2,4]TRIAZOLE; 3 [3 CYCLOPENTYLSULFANYL 5 (4' METHANESULFONYL 2 METHYLBIPHENYL 4 YLOXYMETHYL [1,2,4]TRIAZOL 4 YL]PYRIDINE; 4 (3 AZIDOPHENYL) 3 CYCLOPENTYLSULFANYL 5 PHENOXYMETHYL 4H [1,2,4]TRIAZOLE; 5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOLE 3 THIOL; ANTINEOPLASTIC AGENT; CYCLOPENTYL(5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YL)AMINE; ISOPROPYL(5 PHENOXYMETHYL 4 PHENYL 4H [1,2,4]TRIAZOL 3 YL)AMINE; PROTEIN INHIBITOR; PROTEIN P97; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FIRST PASS EFFECT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 84872815788     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013213     Document Type: Article

References (28)

1. Ogura, T.; Wilkinson, A. J. AAA+ superfamily ATPases: common structure-diverse function Genes Cells 2001, 6, 575-597
2. Wang, Q.; Changcheng Song, C.; Li, C. H. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions J. Struct. Biol. 2004, 146, 44-57
3. DeLaBarre, B.; Brunger, A. T. Nucleotide dependent motion and mechanism of action of p97/VCP J. Mol. Biol. 2005, 347, 437-452
4. Davies, J. M.; Brunger, A. T.; Weis, W. I. Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotide-dependent conformational change Structure 2008, 16, 715-726
5. Muller, J. M.; Deinhardt, K.; Rosewell, I.; Warren, G.; Shima, D. T. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality Biochem. Biophys. Res. Commun. 2007, 354, 459-65
6. Kakizuka, A. Roles of VCP in human neurodegenerative disorders Biochem. Soc. Trans. 2008 Feb, 36 (Pt 1) 105-108
7. Yamamoto, S.; Tomita, Y.; Nakamori, S.; Hoshida, Y.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M.; Aozasa., K. Elevated Expression of Valosin-Containing Protein (p97) in Hepatocellular Carcinoma Is Correlated With Increased Incidence of Tumor Recurrence J. Clin. Oncol. 2003, 21 (3) 447-452
8. Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Takiguchi, S.; Fujiwara, Y.; Yasuda, T.; Yano, M.; Nakamori, S.; Sakon, M.; Monden, M.; Katsuyuki Aozasa, K. Expression Level of Valosin-Containing Protein Is Strongly Associated With Progression and Prognosis of Gastric Carcinoma J. Clin. Oncol. 2003, 21 (13) 2537-2544
9. Wang, Q.; Shinkre, B. A.; Lee, J.; Weniger, M. A.; Liu, Y.; Chen, W.; Wiestner, A.; Trenkle, W. C.; Ye, Y. The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group PLoS One 2010, 5 (11) e15479
10. Choua, T.; Brownb, S. J.; Minondc, D.; Nordind, B. E.; Lie, K.; Jones, A. C.; Chasec, P.; Porubskye, P. R.; Stoltzf, B. M.; Schoenene, F. J.; Patricellid, M. P.; Hodderc, P.; Rosenb, H.; Deshaies, R. J. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (12) 4834-4839
11. Bursavich, M. G.; Parkera, D. P.; Willardsena, J. A.; Gaob, Z.; Davisb, T.; Ostaninb, K.; Robinsonb, R.; Petersonb, A.; Cimborab, D. M.; Zhub, J.; Richards, B. 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97) Bioorg. Med. Chem. Lett. 2010, 20 (5) 1677-1879
12. Li, G.; Huang, C.; Zhao, G.; Lennarz, W. J. Interprotomer motion-transmission mechanism for the hexameric AAA ATPase p97 Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 3737-3741
13. Huang, C.; Li, G.; Lennarz, W. J. Dynamic flexibility of the ATPase p97 is important for its interprotomer motion trasmission Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (25) 9792-9797
14. Maxwell, J. R.; Wasdahl, D. A.; Wolfson, A. C.; Stenberg, V. I. Synthesis of 5-aryl-2 H -tetrazole-2-acetic acids, and [(4-phenyl-5-aryl-4 H -1,2,4-triazol-3-yl)thio]acetic acids as possible superoxide scavengers and antiinflammatory agents J. Med. Chem. 1984, 27, 1565-1570
15. Ivanova, N. V.; Sviridov, S. I.; Shorshnev, S. V.; Stepanov, A. E. A convenient synthesis of 4,5-disubstituted 1,2,4-triazoles functionalized in position 3 Synthesis 2006, 1, 156-160
16. Per Jalilian, A. R.; Sattari, S.; Bineshmarvasti, M.; Shafiee, A.; Daneshtalab, M. Synthesis and in vitro antifungal and cytotoxicity evaluation of thiazolo-4 H -1,2,4-triazoles and 1,2,3-thiadiazolo-4 H -1,2,4-triazoles Arch. Pharm. 2000, 333, 347-354
17. Certain triazoles-based compounds, compositions and uses thereof. (Amphora Discovery Corporation), WO2005/97758 A1, 2005.
18. Takahashi, T.; Sakuraba, A.; Hirohashi, T.; Shibata, T.; Hirose, M.; Haga, Y.; Nonoshita, K.; Kanno, T.; Ito, J.; Iwaasa, H.; Kanatani, A. Novel potent neuropeptide Y Y5 receptor antagonist: synthesis and structure-activity relationships of phenylpiperazine derivatives Bioorg. Med. Chem. 2006, 14, 7501-7511
19. Heuvel, M.; Berg, T. A.; Kellog, R. M.; Choma, C. T.; Feringa, B. L. Synthesis of a non-heme template for attaching four peptides: an approach to artificial iron(II)-containing peroxidases J. Org. Chem. 2004, 69, 250-262
20. 3-Heterocyclic-4-phenyl-triazole derivatives as inhibitors of the vasopressin V1A receptor. (Pfizer Limited). WO2005/105779 A1 2005
21. Coppola, G. M. A new scavenger resin for amines Tetrahedron Lett. 1998, 39, 8233-8236
22. Kakefuda, A.; Takeshi, S.; Takahiko, T.; Atsuo, T.; Shuichi, S.; Shin-ichi, T. Discovery of 4,5-diphenyl-1,2,4-triazole derivatives as a novel class of selective antagonist for the human V1A receptor Bioorg. Med. Chem. 2002, 10, 1905-1912
23. Zwaagstra, M. E.; Timmerman, H.; Tamura, M.; Tohma, T.; Wada, Y. Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of cysLT1 (LTD4) receptor antagonists J. Med. Chem. 1997, 40, 1075-1089
24. Pinna, F.; Menegazzo, F.; Signoretto, M.; Canton, P.; Fagherazzi, G.; Perticone, N. Consecutive hydrogenation of benzaldehyde over Pd catalysts: influence of supports and sulfur poisoning Appl. Catal., A 2002, 219, 195-200
25. Zeyising, B.; Gosch, C.; Terfort, A. Protecting group for thiols suitable for Suzuki conditions Org. Lett. 2000, 13, 1843-1845
26. Ewens, C. A.; Kloppsteck, P.; Förster, A.; Zhang, X.; Freemont, P. S. Structural and functional implications of phosphorylation and acetylation in the regulation of the AAA+ protein p97 Biochem. Cell Biol. 2010, 88, 41-48
27. Fröhlich, K. U.; Fries, H. W.; Peters, J. M.; Mecke, D. The ATPase activity of purified CDC48p from Saccharomyces cerevisiae shows complex dependence on ATP-, ADP-, and NADH-concentrations and is completely inhibited by NEM Biochim. Biophys. Acta 1995, 1253, 25-32
28. Beria, I.; Ballinari, D.; Bertrand, J. A.; Borghi, D.; Bossi, R. T.; Brasca, M. G.; Cappella, P.; Caruso, M.; Ceccarelli, W.; Ciavolella, A.; Cristiani, C.; Croci, V.; De Ponti, A.; Fachin, G.; Ferguson, R. D.; Lansen, J.; Moll, J. K.; Pesenti, E.; Posteri, H.; Perego, R.; Rocchetti, M.; Storici, P.; Volpi, D.; Valsasina, B. Identification of 4,5-Dihydro-1 H -pyrazolo[4,3-h ]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors J. Med. Chem. 2010, 53, 3532-3551